Kingdon Capital Management, L.L.C. Sesen Bio, Inc. Transaction History

Kingdon Capital Management, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.66 $2.86 Million - $6.11 Million	-1,311,672 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$1.3 - $3.24 $520,000 - $1.3 Million	-400,000 Reduced 23.37%	1,311,672 $3.41 Million
Q4 2020 Feb 16, 2021	SELL	$1.01 - $1.77 $37,922 - $66,458	-37,547 Reduced 2.15%	1,711,672 $2.31 Million
Q1 2020 May 15, 2020	SELL	$0.39 - $1.03 $37,594 - $99,288	-96,397 Reduced 5.22%	1,749,219 $981,000
Q4 2019 Feb 14, 2020	SELL	$0.89 - $1.5 $3.84 Million - $6.46 Million	-4,309,707 Reduced 70.02%	1,845,616 $1.92 Million
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.51 $11,286 - $16,386	-10,852 Reduced 0.18%	6,155,323 $7.2 Million
Q2 2019 Aug 14, 2019	BUY	$0.95 - $2.46 $880,287 - $2.28 Million	926,618 Added 17.69%	6,166,175 $9.25 Million
Q4 2018 Feb 14, 2019	BUY	$0.96 - $2.04 $762,240 - $1.62 Million	794,000 Added 17.86%	5,239,557 $7.44 Million
Q2 2018 Aug 14, 2018	BUY	$1.04 - $3.29 $4.62 Million - $14.6 Million	4,445,557 New	4,445,557 $8.67 Million

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.